EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative Multiomics Analysis Reveals a Cancer Stem Cell–Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma

Yang Zi, Ying Zhang, Jun Wu, Jingjing Xie, Xuehua Yan iD

Stem Cells International · 2026-01 · 2026 (1)

DOI: 10.1155/sci/7388629 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stem Cells International, online erschienen am 02.08.2026. Verfasst von Yang Zi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intervention, Inner Mongolia People's Hospital, Hohhot City, Inner Mongolia Autonomous Region, China, nmgyy.cn. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatocellular carcinoma (HCC) suffers from a poor prognosis largely due to its profound molecular heterogeneity and high frequency of relapse, challenges that are closely linked to the biology of cancer stem cells (CSCs) and a lack of effective stemness‐related prognostic biomarkers. Identifying CSC–related prognostic biomarkers and therapeutic targets is critical for improving patient outcomes.

Methods

We integrated differential expression analysis, weighted gene co‐expression network analysis (WGCNA), and CSC gene databases to identify core prognostic genes driven by stemness mechanisms. A robust prognostic model was developed and validated using multiple machine learning algorithms across TCGA and Gene Expression Omnibus (GEO) cohorts. The clinical relevance of the signature was assessed via receiver operating characteristic curve (ROC) curves, survival analysis, and association with tumor stage. Single‐cell RNA sequencing (scRNA‐seq) and computational drug repositioning coupled with molecular docking were employed to explore mechanistic insights and therapeutic candidates.

Results

Intersection analysis identified 12 core genes enriched in CSC–associated pathways. The optimal CoxBoost model demonstrated superior predictive performance for overall survival (OS) in internal, external, and meta‐analyses. The signature’s single‐sample GSEA (ssGSEA) score exhibited high diagnostic accuracy, correlated with advanced tumor stage, and enabled effective risk stratification. Single‐cell analysis revealed DARS2 enrichment in M1 macrophages, suggesting a role for CSCs in modulating the tumor immune microenvironment. The histone deacetylase (HDAC) inhibitor belinostat was prioritized via Drug Signature Database (DSigDB) screening and validated by molecular docking as a candidate for targeting the CSC–related signature.

Conclusion

This study establishes a novel CSC–associated gene signature for diagnosis and prognosis in HCC and nominates belinostat as a repurposing candidate for targeting stemness‐related pathways, offering a promising strategy for personalized therapy.

Schlagwörter

Stichwörter der Autor:innen

belinostatcancer stem cellsdrug repositioninghepatocellular carcinomaprognostic signature

Autor:innen und Institutionen

  • Department of Intervention, Inner Mongolia People's Hospital, Hohhot City, Inner Mongolia Autonomous Region, China, nmgyy.cn.
  • Department of Hepatology, Integrated Traditional Chinese and Western Medicine, Lanzhou Second People's Hospital, Lanzhou City, Gansu Province, China.
  • Department of Radiology, Lanzhou Second People's Hospital, Lanzhou, City, Gansu Province, China.
  • Department of Medical Science, University of Technology Sydney, Sydney, New South Wales, Australia, uts.edu.au.

ORCID-Profile: Xuehua Yan

Zitieren

APA

Zi, Y., Zhang, Y., Wu, J., Xie, J., & Yan, X. (2026). Integrative Multiomics Analysis Reveals a Cancer Stem Cell–Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma. Stem Cells International, 2026(1). https://doi.org/10.1155/sci/7388629

Vancouver

Zi Y, Zhang Y, Wu J, Xie J, Yan X. Integrative Multiomics Analysis Reveals a Cancer Stem Cell–Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma. Stem Cells International. 2026;2026(1). doi:10.1155/sci/7388629

BibTeX
@article{Zi2026,
  author = {Zi, Yang and Zhang, Ying and Wu, Jun and Xie, Jingjing and Yan, Xuehua},
  title = {Integrative Multiomics Analysis Reveals a Cancer Stem Cell–Driven Prognostic Signature and Nominates Belinostat for Targeted Therapy in Hepatocellular Carcinoma},
  journal = {Stem Cells International},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/sci/7388629}
}
Kostenlos starten →